Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.